[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506740":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":27,"responsibleParty":43,"collaborators":45,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"University Hospital Tuebingen","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Group A: Tamoxifen",null,"Patients with early HR+\u002FHER2- Breast cancer receiving Tamoxifen",{"label":13,"type":10,"description":14,"interventionNames":10},"Group B: Aromatase Inhibitor (+GnRH if premenopausal)","Patients with early HR+\u002FHER2- Breast cancer receiving Aromatase Inhibitor (+GnRH if premenopausal)",{"label":16,"type":10,"description":17,"interventionNames":10},"Group C: Control group","no preoperative endocrine treatment",[19],{"name":20,"affiliation":5,"role":21},"Dominik Dannehl, Dr.","PRINCIPAL_INVESTIGATOR",[23],{"name":20,"role":24,"phone":25,"phoneExt":10,"email":26},"CONTACT","07071 29 82211","Dominik.Dannehl@med.uni-tuebingen.de",[28],{"facility":29,"status":30,"city":31,"state":10,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Department of Women's Health","RECRUITING","Tübingen","72076","Germany","DE",{"type":36,"coordinates":37},"Point",[38,39],9.05222,48.52266,{"lat":39,"lon":38},[42],{"name":20,"role":24,"phone":25,"phoneExt":10,"email":26},{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[46,48],{"name":47,"class":6},"University Hospital Ulm",{"name":49,"class":6},"University Hospital Freiburg","100506740","impact-of-endocrine-therapy-menstrual-cycle-pam50-ki67-on-treatment-decisions-in-hr-and-her2--breast-cancer-100506740",false,"NCT05878314","Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer","Impact of Preoperative Endocrine Therapy, Menstrual Cycle, PAM50 Assessment and Ki67 Dynamics on Adjuvant Treatment Decisions in Hormone Receptor-positive and HER2-negative Patients With Early Breast Cancer","Inclusion Criteria:\n\n* women ≥ 18 years of age\n* histologically proven unilateral primary non-metastatic invasive breast cancer\n* Estrogen receptor (ER)-\u002F or Progesterone receptor (PR)- positive and HER2-negative\n* Ki67 from core biopsy is available\n* no lymph-node involvement by clinical evaluation and ultrasound (cN0)\n* not amendable to neoadjuvant chemotherapy\n* surgery or planned surgery at the Department for Women's Health, Tuebingen or Freiburg\n* planned preoperative endocrine treatment with Tamoxifen, Aromatase inhibitors, Goserelin or nothing for 2 - 4 weeks\n* written informed consent\n\nExclusion Criteria:\n\n* ER-negative and PR-negative\n* HER2-positive\n* bilateral breast cancer\n* preexisting cancer disease within the last 10 years\n* preexisting invasive ipsi- or contralateral breast cancer (non-invasive ipsi- or contralateral breast cancer is not regarded as an exclusion criteria)\n* any systemic breast cancer therapy before inclusion into the trial\n* indication for neoadjuvant chemotherapy\n* any systemic therapy except Tamoxifen, Aromatase inhibitors, Goserelin before surgery\n* locally advanced, inoperable or metastatic breast cancer\n* pregnant or lactating patients\n* inadequate general condition (not fit for chemotherapy)\n* hormonal contraception within 6 months before inclusion","FEMALE","18 Years",{"count":60,"type":61},504,"ESTIMATED","OBSERVATIONAL","PEAK is a prospective, multicenter, non-interventional investigator-initiated trial (IIT) that aims to investigate the influence of the menstrual cycle phase on Ki67 in patients who either receive Tamoxifen, Aromatase inhibitors ± gonadotropin-releasing hormone (GnRH)-Analogues or nothing or no preoperative endocrine treatment as part of the clinical routine. The investigators moreover address the question whether PAM50 assessment in addition to Ki67 dynamics still impacts treatment recommendations.",[65],"Hormone Receptor Positive HER-2 Negative Breast Cancer","2026-02-09",{"date":68,"type":69},"2026-02-10","ACTUAL",{"date":71,"type":69},"2023-04-25",{"date":73,"type":61},"2035-04",{"name":5,"class":6},1]